カルバペネム市場- 世界の産業規模、シェア、動向、機会、予測、薬剤クラス別、用途別、流通チャネル別、地域別、競合別、2019-2029年

カルバペネムの世界市場規模は2023年に35億2,000万米ドルとなり、2029年までの予測期間のCAGRは4.25%で着実な成長が予測されています。

世界のカルバペネム市場は、抗生物質耐性菌感染症の増加、高度なヘルスケアソリューションに対する需要の高まり、世界人口の増加により、大きな成長を遂げています。カルバペネム系抗生物質は強力な抗生物質の一種で、さまざまな細菌に対して幅広いスペクトラム活性を示すことで知られ、重篤な感染症との闘いにおいて重要なツールとなっています。抗生物質耐性菌の出現は、世界的に公衆衛生上の大きな脅威となっています。抗生物質の過剰使用と誤用、そして不十分な感染対策が、耐性菌の増加を招いています。特にカルバペネム耐性菌は、重篤な感染症に対する治療の選択肢を狭めてしまうため、懸念の原因となっています。カルバペネム抗生物質は、多剤耐性菌によるものも含め、重症感染症の治療における最後の手段とみなされることが多いです。カルバパピス系抗生物質は、グラム陰性およびグラム陽性の病原体を含む幅広い細菌に対して有効です。この汎用性により、カルバペネム系抗菌薬は、他の抗生物質が効かないような状況でも貴重な戦力となります。世界の人口が増加の一途をたどる中、感染症が蔓延する可能性も高まっています。カルバペネム系抗生物質のような効果的な抗生物質に対する需要は、より広範な感染症に対処する必要性によってもたらされています。抗生物質耐性感染症の急増は、カルバペネム市場の重要な促進要因です。従来の抗生物質が効きにくくなるにつれ、ヘルスケアプロバイダーは、かつては対処可能であった感染症に対処するためにカルバペネム系抗菌薬を使用するようになっています。特に新興国では、ヘルスケア・インフラの改善により医療施設へのアクセスが向上し、カルバペネム系抗生物質のような高度な抗生物質への需要が高まっています。製薬会社は、進化する耐性菌パターンに対処するため、新しい製剤や併用療法の開発に投資しています。こうした技術革新が市場の成長を促進すると期待されています。

市場促進要因

薬剤耐性感染症の増加

世界人口の増加と高齢化

主な市場課題

抗生物質耐性

規制と品質管理

価格設定とアクセシビリティ

主な市場動向

技術の進歩

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 世界のカルバペネム市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 薬剤クラス別（メロペネム、イミペネム、エルタペネム）
  • 用途別（尿路感染症、血流感染症、肺炎、腹腔内感染症、その他）
  • 流通チャネル別（病院薬局、小売薬局、その他）
  • 地域別
  • 企業別（2023）
• 市場マップ
  • 薬剤クラス別
  • 用途別
  • 流通チャネル別
  • 地域別

第5章 アジア太平洋地域のカルバペネム市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 薬剤クラス別
  • 用途別
  • 流通チャネル別
  • 国別
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • オーストラリア
  • 日本
  • 韓国

第6章 欧州のカルバペネム市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 薬剤クラス別
  • 用途別
  • 流通チャネル別
  • 国別
• 欧州：国別分析
  • フランス
  • ドイツ
  • スペイン
  • イタリア
  • 英国

第7章 北米のカルバペネム市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 薬剤クラス別
  • 用途別
  • 流通チャネル別
  • 国別
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第8章 南米のカルバペネム市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 薬剤クラス別
  • 用途別
  • 流通チャネル別
  • 国別
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第9章 中東・アフリカのカルバペネム市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 薬剤クラス別
  • 用途別
  • 流通チャネル別
  • 国別
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第10章 市場力学

• 促進要因
• 課題

第11章 市場動向と発展

• 最近の動向
• 製品上市
• 合併と買収

第12章 世界のカルバペネム市場：SWOT分析

第13章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第14章 競合情勢

• Menarini Group
• Pfizer Inc.
• Sun Pharmaceutical Industries Ltd
• Lupin Limited
• Kopran Limited
• Aurobindo Pharma Limited
• Daewoong Pharmaceuticals Co., Ltd.
• Shenzhen Haibin Pharmaceutical Co. Ltd.
• Merck & Co., Inc.
• Venus Remedies Ltd

第15章 戦略的提言

第16章 調査会社について・免責事項

Global Carbapenem Market was valued at USD 3.52 Billion in 2023 and is anticipated to project steady growth in the forecast period with a CAGR of 4.25% through 2029. The global carbapenem market is experiencing significant growth due to the increasing prevalence of antibiotic-resistant bacterial infections, growing demand for advanced healthcare solutions, and the rising global population. Carbapenems are a class of powerful antibiotics known for their broad-spectrum activity against a wide range of bacteria, making them a critical tool in the fight against serious infections. The emergence of antibiotic-resistant bacteria poses a major public health threat worldwide. Overuse and misuse of antibiotics, coupled with inadequate infection control measures, have led to the rise of resistant strains of bacteria. Carbapenem-resistant bacteria, in particular, are a cause for concern as they limit treatment options for severe infections. Carbapenem antibiotics are often considered a last resort in the treatment of severe infections, including those caused by multidrug-resistant bacteria. They are effective against a broad spectrum of bacteria, including Gram-negative and Gram-positive pathogens. This versatility makes carbapenems a valuable asset in situations where other antibiotics have failed. With the world's population continuing to grow, the potential for infectious diseases to spread is also increasing. The demand for effective antibiotics like carbapenems is driven by the need to combat a wider range of infections. The surge in antibiotic-resistant infections is a significant driver of the carbapenem market. As conventional antibiotics become less effective, healthcare providers are turning to carbapenems to combat infections that were once manageable. Improvements in healthcare infrastructure, especially in emerging economies, have led to increased access to healthcare facilities and a higher demand for advanced antibiotics like carbapenems. Pharmaceutical companies are investing in the development of new carbapenem formulations and combination therapies to address evolving bacterial resistance patterns. These innovations are expected to drive market growth.

Key Market Drivers

Increasing Incidence of Drug-Resistant Infections

The global healthcare landscape is facing a growing crisis in the form of drug-resistant infections. Antibiotics, once hailed as wonder drugs, are increasingly losing their efficacy due to the emergence of antibiotic-resistant bacteria. Among the most formidable of these resistant bacteria are carbapenem-resistant pathogens. This alarming trend has created a surge in demand for carbapenem antibiotics, driving the global carbapenem market. The increasing incidence of drug-resistant infections is a serious global health concern. Antibiotic resistance occurs when bacteria evolve mechanisms to survive exposure to antibiotics. This resistance can develop naturally over time, but it is accelerated by the overuse and misuse of antibiotics in human and animal healthcare.

Antibiotics are often prescribed unnecessarily or inappropriately for viral infections that do not respond to antibiotics. This overuse of antibiotics can promote the development of resistant strains of bacteria. In healthcare facilities, inadequate infection control measures can lead to the spread of drug-resistant bacteria. This is especially problematic in hospitals and long-term care settings. Antibiotics are used in animal agriculture to promote growth and prevent disease. This practice contributes to the spread of antibiotic-resistant bacteria in both animals and the environment, which can subsequently affect human health. The interconnected nature of our world allows for the rapid spread of drug-resistant bacteria across borders.

The increasing incidence of drug-resistant infections is driving significant growth in the global carbapenem market. Pharmaceutical companies are investing in research and development to create new carbapenem drugs and to extend the patent life of existing ones. The market is also witnessing increased production and distribution of these antibiotics to meet growing demand. Furthermore, governments and healthcare organizations are taking steps to address the issue of antibiotic resistance through improved stewardship programs, better infection control practices, and regulation of antibiotic use in both human and veterinary medicine. These measures aim to slow the emergence of new drug-resistant bacteria and extend the utility of existing antibiotics, including carbapenems.

Rising Global Population and Aging Demographics

The global healthcare landscape is continuously evolving, with several factors contributing to the increasing demand for advanced medical treatments. Two significant factors influencing the pharmaceutical industry are the rising global population and aging demographics. The convergence of these trends has a substantial impact on the healthcare sector, particularly in the context of antimicrobial drugs like carbapenems. The world's population is on a steady upward trajectory, with the United Nations estimating that it will reach 9.7 billion by 2050. This population growth is accompanied by increased urbanization, higher population density, and easier transmission of infectious diseases. A larger population means a higher number of people susceptible to bacterial infections, and this has led to an increased demand for antibiotics like carbapenems. As countries continue to develop, access to healthcare services is also improving, leading to increased diagnosis and treatment of various medical conditions, including bacterial infections. In densely populated urban areas, where people often live in close quarters, the risk of infectious diseases spreading quickly is amplified. This underscores the importance of potent antibiotics like carbapenems to combat potentially deadly infections effectively.

Another pivotal demographic shift is the aging of populations in many parts of the world. The proportion of elderly individuals is increasing due to longer life expectancy and declining birth rates. As people age, their immune systems weaken, making them more susceptible to infections. Additionally, the elderly often have multiple chronic health conditions that require medical intervention, which can expose them to healthcare-associated infections. Carbapenems are essential in the management of bacterial infections in the elderly population, especially when dealing with complex cases that may involve multi-drug-resistant bacteria. As the global population continues to age, the demand for these antibiotics is likely to rise significantly.

One of the most pressing concerns in healthcare today is the emergence of antibiotic-resistant bacteria. The misuse and overuse of antibiotics have accelerated the development of resistant strains, making it increasingly difficult to treat common infections. In this context, carbapenems play a critical role as a last line of defense against resistant pathogens. The rising global population and aging demographics contribute to the increasing incidence of antibiotic-resistant infections. Infections that were once easily treatable are becoming more challenging to manage. This scenario has further propelled the demand for carbapenems, as they are often the only effective treatment option in these cases.

Key Market Challenges

Antibiotic Resistance

The primary challenges facing the global carbapenem market is the emergence of antibiotic resistance. Overuse and misuse of antibiotics have led to the development of antibiotic-resistant strains of bacteria, including carbapenem-resistant organisms (CROs). Carbapenems are often considered the last line of defense against such infections, and their effectiveness is compromised when resistance develops. This trend has significant implications for patient outcomes and healthcare costs, as more expensive and less effective treatments may be required.

Regulatory and Quality Control

The manufacturing and distribution of antibiotics, including carbapenems, are subject to stringent regulatory requirements and quality control measures. This can pose a challenge for both established and new market entrants. Stringent regulations are necessary to ensure the safety and efficacy of these life-saving drugs, but they can result in delays and increased costs for production, which may limit access in some regions.

Pricing and Accessibility

The pricing of carbapenems has been a contentious issue in the global market. These antibiotics are often more expensive than other antibiotic classes due to their potency and effectiveness. High prices can limit accessibility, particularly in low- and middle-income countries. The challenge is to strike a balance between ensuring affordability for patients and providing incentives for pharmaceutical companies to continue developing and producing these critical drugs.

Key Market Trends

Technological Advancements

In the rapidly evolving landscape of healthcare, technological advancements play a pivotal role in the development of novel treatments and therapies to combat various diseases. One such area of medical advancement that has gained significant attention is the Global Carbapenem Market. Carbapenems are a class of antibiotics used to treat serious infections caused by multi-drug resistant bacteria, making them a critical component of modern healthcare. The global carbapenem market is experiencing robust growth, driven by technological innovations in pharmaceutical research and development.

Technological advancements have revolutionized the process of drug discovery and development in the pharmaceutical industry. In recent years, innovations such as artificial intelligence, machine learning, and high-throughput screening have accelerated the identification of potential drug candidates, including new carbapenem antibiotics. These advancements have made the drug development process more efficient and cost-effective, leading to the introduction of novel carbapenem compounds that are more potent and have fewer side effects. Another critical aspect of technological advancement in the healthcare industry is the move toward precision medicine. This approach involves tailoring medical treatments to the individual characteristics of each patient. In the context of carbapenems, precision medicine can help healthcare providers select the most suitable antibiotic based on the specific strain of bacteria causing the infection. Genetic sequencing and diagnostic tools are now available to identify bacterial strains and their antibiotic susceptibility, ensuring that the right carbapenem is prescribed for optimal treatment outcomes. Advancements in pharmaceutical technology have also led to improved formulations and delivery systems for carbapenem antibiotics. These innovations have made it easier for healthcare providers to administer the drugs, resulting in better patient compliance and treatment outcomes. New formulations may include extended-release versions or more convenient dosing schedules, further enhancing the effectiveness of carbapenem treatment.

Segmental Insights

Drug Class Insight

Based on the category of drug class, Meropenem emerged as the dominant player in the global market for Carbapenem in 2023. Meropenem possesses a broad-spectrum of activity, which means it is effective against a wide range of bacteria, including both Gram-positive and Gram-negative organisms. This versatility makes it a preferred choice for treating complex infections where the causative agent may not be readily identified. Meropenem has excellent stability against bacterial enzymes called carbapenemases, which often render other antibiotics ineffective. This stability gives it an edge in treating infections caused by carbapenem-resistant bacteria, a growing concern in healthcare. Meropenem has been extensively studied and proven to be highly effective in clinical trials, making it a trusted choice for healthcare professionals. It has demonstrated remarkable results in various clinical settings, including intensive care units. Meropenem is typically administered intravenously, making it suitable for patients in critical care settings. Its ease of use and compatibility with various administration methods contribute to its popularity.

Application Insights

The Urinary Tract Infections segment is projected to experience rapid growth during the forecast period. Urinary tract infections are among the most common bacterial infections globally. They primarily affect the urinary system, including the bladder, urethra, ureters, and kidneys. UTIs are typically caused by bacteria, and Escherichia coli (E. coli) is the most common culprit. UTIs can vary in severity, ranging from uncomplicated cases that affect the bladder to more severe and potentially life-threatening kidney infections. UTIs can affect individuals of all ages, but women are more prone to developing them due to anatomical differences. Factors such as sexual activity, pregnancy, and the use of certain types of birth control can increase the risk of UTIs. Additionally, individuals with underlying health conditions, weakened immune systems, or urinary tract abnormalities are at higher risk.

Regional Insights

North America emerged as the dominant region in the global Carbapenem market in 2023, holding the largest market share in terms of value. North America, particularly the United States, is a hotbed of pharmaceutical innovation. Many leading pharmaceutical companies based in the region are pioneers in the development and production of carbapenems. The robust research and development infrastructure, as well as a commitment to combating antibiotic-resistant infections, drive innovation in this market. North America is not immune to the global rise in antibiotic resistance. The region faces an increasing burden of multi-drug resistant bacterial infections, including those caused by healthcare-associated infections, community-acquired infections, and opportunistic pathogens. As a result, healthcare providers have had to turn to carbapenems more frequently to effectively combat these challenging infections.

Key Market Players

Menarini Group

Pfizer Inc.

Sun Pharmaceutical Industries Ltd

Lupin Limited

Kopran Limited

Aurobindo Pharma Limited

Daewoong Pharmaceuticals Co., Ltd.

Shenzhen Haibin Pharmaceutical Co. Ltd.

Merck & Co., Inc.

Venus Remedies Ltd

Report Scope:

In this report, the Global Carbapenem Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Carbapenem Market, By Drug Class:

Meropenem Imipenem Ertapenem

Carbapenem Market, By Application:

Urinary Tract Infections Blood Stream Infections Pneumonia Intra-abdominal Infections Others

Carbapenem Market, By Distribution Channel:

Hospital Pharmacies Retail Pharmacies Others

Carbapenem Market, By Region:

North America

United States

Canada

Mexico

Europe

France

United Kingdom

Italy

Germany

Spain

Asia-Pacific

China

India

Japan

Australia

South Korea

South America

Brazil

Argentina

Colombia

Middle East & Africa

South Africa

Saudi Arabia

UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Carbapenem Market.

Available Customizations:

Global Carbapenem market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Global Carbapenem Market Outlook

• 4.1. Market Size & Forecast
  • 4.1.1. By Value
• 4.2. Market Share & Forecast
  • 4.2.1. By Drug Class (Meropenem, Imipenem, Ertapenem)
  • 4.2.2. By Application (Urinary Tract Infections, Blood Stream Infections, Pneumonia, Intra-abdominal Infections, Others)
  • 4.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Others)
  • 4.2.4. By Region
  • 4.2.5. By Company (2023)
• 4.3. Market Map
  • 4.3.1. By Drug Class
  • 4.3.2. By Application
  • 4.3.3. By Distribution Channel
  • 4.3.4. By Region

5. Asia Pacific Carbapenem Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Drug Class
  • 5.2.2. By Application
  • 5.2.3. By Distribution Channel
  • 5.2.4. By Country
• 5.3. Asia Pacific: Country Analysis
  • 5.3.1. China Carbapenem Market Outlook
    • 5.3.1.1. Market Size & Forecast
      • 5.3.1.1.1. By Value
    • 5.3.1.2. Market Share & Forecast
      • 5.3.1.2.1. By Drug Class
      • 5.3.1.2.2. By Application
      • 5.3.1.2.3. By Distribution Channel
  • 5.3.2. India Carbapenem Market Outlook
    • 5.3.2.1. Market Size & Forecast
      • 5.3.2.1.1. By Value
    • 5.3.2.2. Market Share & Forecast
      • 5.3.2.2.1. By Drug Class
      • 5.3.2.2.2. By Application
      • 5.3.2.2.3. By Distribution Channel
  • 5.3.3. Australia Carbapenem Market Outlook
    • 5.3.3.1. Market Size & Forecast
      • 5.3.3.1.1. By Value
    • 5.3.3.2. Market Share & Forecast
      • 5.3.3.2.1. By Drug Class
      • 5.3.3.2.2. By Application
      • 5.3.3.2.3. By Distribution Channel
  • 5.3.4. Japan Carbapenem Market Outlook
    • 5.3.4.1. Market Size & Forecast
      • 5.3.4.1.1. By Value
    • 5.3.4.2. Market Share & Forecast
      • 5.3.4.2.1. By Drug Class
      • 5.3.4.2.2. By Application
      • 5.3.4.2.3. By Distribution Channel
  • 5.3.5. South Korea Carbapenem Market Outlook
    • 5.3.5.1. Market Size & Forecast
      • 5.3.5.1.1. By Value
    • 5.3.5.2. Market Share & Forecast
      • 5.3.5.2.1. By Drug Class
      • 5.3.5.2.2. By Application
      • 5.3.5.2.3. By Distribution Channel

6. Europe Carbapenem Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Drug Class
  • 6.2.2. By Application
  • 6.2.3. By Distribution Channel
  • 6.2.4. By Country
• 6.3. Europe: Country Analysis
  • 6.3.1. France Carbapenem Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Drug Class
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. Germany Carbapenem Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Drug Class
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Spain Carbapenem Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Drug Class
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By Distribution Channel
  • 6.3.4. Italy Carbapenem Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Drug Class
      • 6.3.4.2.2. By Application
      • 6.3.4.2.3. By Distribution Channel
  • 6.3.5. United Kingdom Carbapenem Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Drug Class
      • 6.3.5.2.2. By Application
      • 6.3.5.2.3. By Distribution Channel

7. North America Carbapenem Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drug Class
  • 7.2.2. By Application
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Country
• 7.3. North America: Country Analysis
  • 7.3.1. United States Carbapenem Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Drug Class
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. Mexico Carbapenem Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Drug Class
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. Canada Carbapenem Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Drug Class
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By Distribution Channel

8. South America Carbapenem Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Drug Class
  • 8.2.2. By Application
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
• 8.3. South America: Country Analysis
  • 8.3.1. Brazil Carbapenem Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Drug Class
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. Argentina Carbapenem Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Drug Class
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. Colombia Carbapenem Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Drug Class
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By Distribution Channel

9. Middle East and Africa Carbapenem Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Drug Class
  • 9.2.2. By Application
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Country
• 9.3. MEA: Country Analysis
  • 9.3.1. South Africa Carbapenem Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Drug Class
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. Saudi Arabia Carbapenem Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Drug Class
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. UAE Carbapenem Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Drug Class
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By Distribution Channel

10. Market Dynamics

• 10.1. Drivers
• 10.2. Challenges

11. Market Trends & Developments

• 11.1. Recent Developments
• 11.2. Product Launches
• 11.3. Mergers & Acquisitions

12. Global Carbapenem Market: SWOT Analysis

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Product

14. Competitive Landscape

• 14.1. Menarini Group
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Product & Services
  • 14.1.4. Financials (In case of listed)
  • 14.1.5. Recent Developments
  • 14.1.6. SWOT Analysis
• 14.2. Pfizer Inc.
• 14.3. Sun Pharmaceutical Industries Ltd
• 14.4. Lupin Limited
• 14.5. Kopran Limited
• 14.6. Aurobindo Pharma Limited
• 14.7. Daewoong Pharmaceuticals Co., Ltd.
• 14.8. Shenzhen Haibin Pharmaceutical Co. Ltd.
• 14.9. Merck & Co., Inc.
• 14.10. Venus Remedies Ltd

15. Strategic Recommendations

16. About Us & Disclaimer